Home Newsfeeds Nio Could Launch an EV Brand Priced as Low as $15,000, According to 36KR

Nio Could Launch an EV Brand Priced as Low as $15,000, According to 36KR

https://36kr.com/p/1847998437707138 (Chinese) https://cnevpost.com/2022/08/01/nio-plans-to-launch-third-brand/ (English)

byCharles Gross

August 1, 2022

1 minute read

https://36kr.com/p/1847998437707138 (Chinese)

https://cnevpost.com/2022/08/01/nio-plans-to-launch-third-brand/ (English)

Roblox Studio Boss Addresses Children Making Money On The Platform: ‘They Didn’t Feel Exploited’

By Franca Quarneti

April 4, 6:04 PM

Explore the controversy surrounding Roblox's treatment of children developers. Roblox Studio chief addresses accusations of exploitation.

RBLX

Acumen Pharmaceuticals Presents Late-Breaker Phase 1 Updates Exploring Novel Target Engagement, Dosing Regimen And Safety Findings For ACU193 In Early Alzheimer’s Disease At The 16th Annual Clinical Trials On Alzheimer’s Disease

By Benzinga Newsdesk

October 27, 9:29 AM

- Acumen presented data exploring target engagement modeling of ACU193, the first clinical-stage amyloid beta oligomer (AβO)-targeting antibody, to inform dose selection, plus further analyses of dose-related amyloid

ABOS

Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B And MTAP Deletions

By Happy Mohamed

December 18, 10:04 AM

- Patient Pharmacodynamic Data Show Decrease in CDKN2A, CDKN2B, and PRMT5 Protein Levels - - A Squamous Non-Small Cell Lung Cancer Patient with CDKN2B Deletion Achieved Marked Tumor Shrinkage after One Cycle

CYCC

Stifel Maintains Buy on Lululemon Athletica, Raises Price Target to $450

By Benzinga Newsdesk

December 5, 10:53 AM

Stifel analyst Jim Duffy maintains Lululemon Athletica (NASDAQ:LULU) with a Buy and raises the price target from $400 to $450.

LULU

Nio Could Launch an EV Brand Priced as Low as $15,000, According to 36KR

Related Posts

Roblox Studio Boss Addresses Children Making Money On The Platform: ‘They Didn’t Feel Exploited’

Acumen Pharmaceuticals Presents Late-Breaker Phase 1 Updates Exploring Novel Target Engagement, Dosing Regimen And Safety Findings For ACU193 In Early Alzheimer’s Disease At The 16th Annual Clinical Trials On Alzheimer’s Disease

Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B And MTAP Deletions

Stifel Maintains Buy on Lululemon Athletica, Raises Price Target to $450